Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-01-16FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol (carbamazepine) filed by Novartis Pharmaceuticals Corporation. The action pertains to c…
-
FDA label_change · 2014-01-16FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol (carbamazepine) filed by Novartis, leading to changes to the product labeling.
-
FDA approval · 2014-01-16FDA Approved: PHENYTOIN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for phenytoin submitted by Sun Pharmaceutical Industries, Inc., approving changes to the product.
-
FDA approval · 2014-01-16FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2014-01-16FDA Approved: ONFI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for ONFI (clobazam) submitted by Lundbeck Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-01-16FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2014-01-16FDA Approved: TEGRETOL XR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol XR (carbamazepine) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2014-01-14Clinical Trial Update: Brain Stimulation for Epilepsy Long Term Follow-up
Long-term follow-up results from a brain stimulation trial for epilepsy have been reported. The update indicates continued safety and effect…
-
CLINICAL_TRIALS trial_result · 2014-01-10Clinical Trial Update: Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures [Phase 2]
Phase 2 double-blind crossover trial evaluating fish oil (EPA and DHA) for intractable partial seizures has completed with results posted.
-
FDA approval · 2014-01-08FDA Approved: PHENYTEK — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for PHENYTEK, allowing an extended phenytoin sodium formulation to be marketed under the ANDA, b…
-
FDA approval · 2014-01-07FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for Ethosuximide from Bionpharma Inc. under ANDA040430.
-
FDA approval · 2014-01-03FDA Approved: EXTENDED PHENYTOIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves a supplemental application to market Extended Phenytoin Sodium (phenytoin sodium) from Amneal Pharmaceuticals LLC.
-
FDA approval · 2014-01-03FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2013-12-31FDA Approved: EXTENDED PHENYTOIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for an extended-release formulation of phenytoin sodium by Amneal Pharmaceuticals.
-
FDA approval · 2013-12-26FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN (Extended Phenytoin Sodium) submitted by Viatris Specialty LLC.
-
FDA approval · 2013-12-26FDA Approved: PHENYTOIN INFATABS — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Phenytoin Infatabs (phenytoin) submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2013-12-24Clinical Trial Update: RNS® System Feasibility Study [Phase 2]
Phase 2 feasibility results for NeuroPace's RNS System in epilepsy, with the study completed and results posted in 2013.
-
FDA approval · 2013-12-23FDA Approved: LAMOTRIGINE — Original Application (Torrent Pharmaceuticals Limited)
FDA approves Torrent Pharmaceuticals Limited's generic lamotrigine through an Original Application (ANDA). Lamotrigine is used to treat epil…
-
FDA approval · 2013-12-20FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for LAMICTAL (lamotrigine) filed by GlaxoSmithKline LLC.
-
FDA approval · 2013-12-20FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal ODT (lamotrigine) from GlaxoSmithKline LLC.
-
FDA label_change · 2013-12-20FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for LAMICTAL (lamotrigine) submitted by GlaxoSmithKline LLC. The supplemental approval resulted …
-
FDA approval · 2013-12-20FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
FDA approves a supplemental application for Lamictal XR (lamotrigine) submitted by GlaxoSmithKline LLC.
-
CLINICAL_TRIALS research · 2013-12-11Clinical Trial Update: Managing Epilepsy Well- WebEase Project [NA]
Completed clinical trial update on the WebEase Project for epilepsy management, sponsored by Emory University.
-
CLINICAL_TRIALS trial_result · 2013-12-06Clinical Trial Update: Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures [Phase 2]
Phase 2 study assessing safety and tolerability of a 15-minute intravenous infusion of levetiracetam in patients with partial onset seizures…
-
CLINICAL_TRIALS trial_result · 2013-12-04Clinical Trial Update: Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy [Phase 2]
Open-label extension study evaluating the safety and seizure frequency of lacosamide in people with epilepsy and primary generalized tonic-c…